<DOC>
	<DOCNO>NCT01123304</DOCNO>
	<brief_summary>This research do find safety MORAb-028 subject metastatic melanoma .</brief_summary>
	<brief_title>Safety Study Human IgM ( MORAb-028 ) Treat Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm AJCC Stage IIIB , IIIC IV melanoma injectable metastasis ( transit , intradermal , subcutaneous nodule ) Tumor accessible intratumoral injection Cumulative tumor volume great enough accept MORAb028 injection give dose level , base intent inject concentration 1 mg/cm3 Are candidate curative surgical excision lymphadenectomy Prior nonsurgical treatment within 4 week Known central nervous system ( CNS ) tumor involvement metastases Hypersensitivity MORAb028</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>melanoma</keyword>
</DOC>